company background image
CVAC

CureVac NasdaqGM:CVAC Stock Report

Last Price

US$11.25

Market Cap

US$2.1b

7D

7.6%

1Y

-37.2%

Updated

27 Jan, 2023

Data

Company Financials +

CVAC Stock Overview

CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA).

CVAC fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

My Notes

New

Notes are coming soon

CureVac N.V. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for CureVac
Historical stock prices
Current Share PriceUS$11.25
52 Week HighUS$20.60
52 Week LowUS$5.63
Beta2.5
1 Month Change95.82%
3 Month Change48.03%
1 Year Change-37.15%
3 Year Changen/a
5 Year Changen/a
Change since IPO-79.87%

Recent News & Updates

An Intrinsic Calculation For CureVac N.V. (NASDAQ:CVAC) Suggests It's 46% Undervalued

Jan 08
An Intrinsic Calculation For CureVac N.V. (NASDAQ:CVAC) Suggests It's 46% Undervalued

Recent updates

An Intrinsic Calculation For CureVac N.V. (NASDAQ:CVAC) Suggests It's 46% Undervalued

Jan 08
An Intrinsic Calculation For CureVac N.V. (NASDAQ:CVAC) Suggests It's 46% Undervalued

Will CureVac (NASDAQ:CVAC) Spend Its Cash Wisely?

May 29
Will CureVac (NASDAQ:CVAC) Spend Its Cash Wisely?

Analysts Are Betting On CureVac N.V. (NASDAQ:CVAC) With A Big Upgrade This Week

May 02
Analysts Are Betting On CureVac N.V. (NASDAQ:CVAC) With A Big Upgrade This Week

A Look At The Intrinsic Value Of CureVac N.V. (NASDAQ:CVAC)

Oct 28
A Look At The Intrinsic Value Of CureVac N.V. (NASDAQ:CVAC)

An Intrinsic Calculation For CureVac N.V. (NASDAQ:CVAC) Suggests It's 31% Undervalued

Jun 13
An Intrinsic Calculation For CureVac N.V. (NASDAQ:CVAC) Suggests It's 31% Undervalued

CureVac N.V.'s (NASDAQ:CVAC) Has Found A Path To Profitability

May 02
CureVac N.V.'s (NASDAQ:CVAC) Has Found A Path To Profitability

How Much Of CureVac N.V. (NASDAQ:CVAC) Do Insiders Own?

Mar 03
How Much Of CureVac N.V. (NASDAQ:CVAC) Do Insiders Own?

Analysts Are Optimistic We'll See A Profit From CureVac N.V. (NASDAQ:CVAC)

Jan 27
Analysts Are Optimistic We'll See A Profit From CureVac N.V. (NASDAQ:CVAC)

Have Insiders Been Buying CureVac N.V. (NASDAQ:CVAC) Shares?

Dec 23
Have Insiders Been Buying CureVac N.V. (NASDAQ:CVAC) Shares?

Shareholder Returns

CVACUS BiotechsUS Market
7D7.6%0.7%2.3%
1Y-37.2%7.1%-9.7%

Return vs Industry: CVAC underperformed the US Biotechs industry which returned 10.5% over the past year.

Return vs Market: CVAC underperformed the US Market which returned -8.5% over the past year.

Price Volatility

Is CVAC's price volatile compared to industry and market?
CVAC volatility
CVAC Average Weekly Movement16.2%
Biotechs Industry Average Movement12.2%
Market Average Movement6.9%
10% most volatile stocks in US Market17.3%
10% least volatile stocks in US Market2.9%

Stable Share Price: CVAC is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 16% a week.

Volatility Over Time: CVAC's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
2000824Franz-Werner Haashttps://www.curevac.com

CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratiory syncytial virus, rotavirus, malaria, and universal influenza. The company also develops RNA-based cancer immunotherapies, including CV8102, which is in Phase 1 clinical trial for treating cutaneous melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck.

CureVac N.V. Fundamentals Summary

How do CureVac's earnings and revenue compare to its market cap?
CVAC fundamental statistics
Market CapUS$2.14b
Earnings (TTM)-US$133.05m
Revenue (TTM)US$105.58m

20.3x

P/S Ratio

-16.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
CVAC income statement (TTM)
Revenue€96.96m
Cost of Revenue€168.04m
Gross Profit-€71.08m
Other Expenses€51.10m
Earnings-€122.18m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.64
Gross Margin-73.31%
Net Profit Margin-126.02%
Debt/Equity Ratio0%

How did CVAC perform over the long term?

See historical performance and comparison